Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | PDE9A | O76083 | 4/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210695 | 0.82 | AHR (0.55) | AHRMAPTCYP3A4ALDH1A1GPR3 | |
| SCHEMBL6545651 | 0.82 | AHR (0.55) | AHRMAPTCYP3A4ALDH1A1GPR3 | |
| SCHEMBL2464667 | 0.79 | PDE9A (0.49) | AHRPDE9APDE1CMAPTALDH1A1 | |
| SCHEMBL29635217 | 0.79 | PDE9A (0.49) | AHRPDE9APDE1CMAPTALDH1A1 | |
| SCHEMBL15926509 | 0.78 | PDE9A (0.47) | AHRPDE9APDE1CMAPTALDH1A1 | |
| SCHEMBL17185603 | 0.78 | PDE9A (0.47) | AHRPDE9APDE1CMAPTALDH1A1 | |
| SCHEMBL25929859 | 0.78 | PDE9A (0.47) | AHRPDE9APDE1CMAPTALDH1A1 | |
| SCHEMBL1514832 | 0.78 | PDE9A (0.47) | AHRPDE9APDE1CMAPTALDH1A1 | |
| SCHEMBL5858501 | 0.78 | PLA2G1B (0.59) | PDE9APDE1CMAPTALDH1A1GPR3 | |
| SCHEMBL27975620 | 0.78 | PDE9A (0.47) | AHRPDE9APDE1CMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203482-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | Bridgestone Corporation (JP) | 2010-07-07 | — | — | EP | claimed |
| WO-2009051702-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2009-04-23 | — | — | WO | claimed |
| WO-2009051700-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (US) | 2009-04-23 | — | — | WO | claimed |
| EP-3458488-A1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | Bridgestone Corporation (JP) | 2019-03-27 | — | — | EP | disclosed |
| CN-109369502-A | A kind of indomethacin derivatives and its preparation method and application | 宜春学院 | 2019-02-22 | — | — | CN | disclosed |
| CN-109153674-A | Iminothiadiazine dioxide derivatives as inhibitors of plasmepsin V of plasmodium | UCB生物制药私人有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017201397-A1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORPORATION (JP) | 2017-11-23 | — | — | WO | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| US-7465738-B2 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| EP-1276721-A2 | METHYLATION OF INDOLE COMPOUNDS USING DIMETHYL CARBONATE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-22 | — | — | EP | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001081305-A2 | METHYLATION OF INDOLE COMPOUNDS USING DIMETHY CARBONATE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | AHR 3912/4885PDE9A 3651/4885PDE1C 3749/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | AHR 4675/4885PDE9A 3358/4885PDE1C 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.